<DOC>
	<DOCNO>NCT02124785</DOCNO>
	<brief_summary>The purpose study ass long-term persistence immunity hepatitis A adult vaccinate 21-25 year earlier hepatitis A vaccine , Havrix® .</brief_summary>
	<brief_title>Evaluation Long-term Persistence Hepatitis A Antibodies Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline ( GSK ) Biologicals ' Hepatitis A Vaccine , Havrix®</brief_title>
	<detailed_description>This long-term persistence study subject participate primary study HAV-112 ( 208109/108 ) HAV-123 ( 208109/114 ) receive additional dose hepatitis A vaccine since , invite provide blood sample Years 21 25 second vaccine dose . No vaccine administer study period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Hepatitis A Antibodies</mesh_term>
	<criteria>A male female receive two dos Havrix study HAV112 ( 208109/108 ) HAV123 ( 208109/114 ) , receive booster dose since . Subjects , opinion investigator , comply requirement protocol ( e.g . return followup visit ) . Written inform consent obtain subject . History hepatitis A disease since completion primary vaccination series study HAV112 ( 208109/108 ) HAV123 ( 208109/114 ) . Administration hepatitis A vaccine time since completion primary vaccination series study HAV112 ( 208109/108 ) HAV123 ( 208109/114 ) include challenge dose study vaccine , part study procedure , longterm persistence phase . Any confirm suspected immunosuppressive immunodeficient condition , base medical history . Administration hepatitis A immunoglobulin and/or blood product and/or longacting immunemodifying drug within six month prior study entry . Chronic administration immunosuppressant immunemodifying drug within six month prior study entry . For corticosteroid , mean prednisone ≥ 20 mg/day , equivalent . Inhaled topical steroid allow . Administration longacting immunemodifying drug within six month prior study entry ( e.g . infliximab ) . Concurrently participate another clinical study period start 30 day end 30 day study visit , subject expose investigational noninvestigational vaccine/product ( pharmaceutical product device ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Long-term persistence</keyword>
	<keyword>Havrix</keyword>
	<keyword>Hepatitis A</keyword>
</DOC>